Summarize, there are several strengths to convince our conclusions including add the control group as the baseline, increase the follow-up time to 2 years to decrease the effect induced by some antiplatelet agents after PCI etc. However, the limitations should be addressed as well, for instance, the number of enrolled patients should be increased, and the differences of LOX-1 in terms of ethnicity, sex, and specific cardiovascular diseases, which may influence the overall conclusion, should be investigated. Here, OLR1 is linked to cardiovascular disorder.